HO

Hematological Oncology

Hematological Oncology is a peer-reviewed journal at the interface of hematology and oncology research. It publishes experimental and clinical articles on blood cancers and neoplastic diseases of the hemopoietic and lymphoid systems, including translational studies, clinical practice and management of hematological neoplasia, diagnostic investigations, imaging and laboratory assays, and therapeutic issues.

Looking to publish in Hematological Oncology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Existing customer login
Subject Hematology, Oncology
Impact Factor 3.9
Quartile Q1
Open Access Type Hybrid
ISSN 0278-0232
eISSN 1099-1069
Invitation Only No
Cost Range $4,880 USD / £3,270 GBP / €4,110 EUR APC for open access articles if accepted and published.

Submission Instructions

Hematological Oncology accepts the following article types. Click on an article type to view submission instructions.

Original Article

Cover Letter A covering letter signed by the corresponding author is required. The covering letter must state that all authors confirm the work has not been published and is not being considered for publication elsewhere.
Abstract An abstract is required. The abstract must be unstructured and less than 300 words. The abstract must be unstructured.
Manuscript The article must not exceed 3000 words excluding references. The main body must be formatted as introduction, materials and methods, results, discussion, and conclusion. The manuscript must include 3-6 keywords and a data availability statement.
References Original Articles may include a maximum of 80 references. References must follow AMA style.
Figures & Tables Figures must not be embedded in the Word document and may be submitted as separate files. Figures and tables must have legends.
Reformat to Hematological Oncology using Livewrite Premium

Review

Cover Letter A covering letter signed by the corresponding author is required. The covering letter must state on behalf of all authors that the work has not been published and is not being considered for publication elsewhere.
Abstract An abstract is required. The abstract must be unstructured and less than 300 words. The abstract must be unstructured.
Manuscript The main body must be formatted as introduction, materials and methods, results, discussion, and conclusion. The manuscript must include 3-6 keywords and a data availability statement.
References References must follow AMA style. References may be submitted in any consistent style or format at initial submission, but the manuscript references must follow AMA style.
Figures & Tables Figures must not be embedded in the Word document and should be uploaded as separate files. Figures and tables must include legends, and tables must be supplied as editable files rather than pasted as images.
Reformat to Hematological Oncology using Livewrite Premium

Letter To The Editor

Cover Letter A covering letter signed by the corresponding author must be included. The covering letter must state that all authors confirm the work has not been published and is not under consideration elsewhere.
Abstract Abstract must not exceed 300 words. Abstract must be unstructured.
Manuscript Article must not exceed 3000 words excluding references. Main body must be formatted as introduction, materials and methods, results, discussion, and conclusion. Manuscript must include a data availability statement and 3-6 keywords.
References Reference list may include a maximum of 10 references. References must follow AMA style.
Figures & Tables Figures must not be embedded in the Word document and may be uploaded as separate files. Figures and tables must include legends.
Reformat to Hematological Oncology using Livewrite Premium

Case Report

Cover Letter A covering letter signed by the corresponding author must be included.
Abstract An abstract is required. Abstract must be unstructured and less than 100 words. Abstract must be unstructured.
Manuscript Case Reports must not exceed 1,500 words. Manuscript must include the sections abstract, introduction, methods, results, and conclusions. Manuscript must include a data availability statement and 3-6 keywords.
References Case Reports may include a maximum of 10 references. References must follow AMA style.
Figures & Tables Figures must not be embedded in the Word document. Figures and tables must have legends.
Reformat to Hematological Oncology using Livewrite Premium

Recent Publications

Autologous Stem Cell Transplant Consolidation Is Associated With Improved Overall Survival in Angioimmunoblastic T‐Cell Lymphoma: A Real‐World National Cancer Database Study

Yu Tao, Huijun Li, Ayo S. Falade, Richard C. Godby, Steven R. Hwang, Grzegorz S. Nowakowski, Urshila Durani, Yun Kyoung Tiger, N. Nora Bennani, Stephen M. Ansell, Yucai Wang, Jihao Zhou

10.1002/hon.70222
View Publication

Clinical Impact of BTK Inhibitor Exposure in LymphGen‐Defined MCD Diffuse Large B‐Cell Lymphoma

Shiyu Jiang, Yizhen Liu, Ran Wei, Wenhao Zhang, Longlong Bao, Jia Jin, Fangfang Lv, Chuanxu Liu, Xiaojian Liu, Hui Sun, Jiachen Wang, Rong Tao, Junning Cao, Xiaoyan Zhou, Qunling Zhang

10.1002/hon.70224
View Publication

Cost‐Effectiveness of Epcoritamab Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab for Relapsed/Refractory Follicular Lymphoma: A US Payer Perspective

Yongtao He, Meiyu Wu, Andong Li, Yangke Yi, Xiaomin Wan

10.1002/hon.70221
View Publication

Real‐World Luspatercept Evidence in Myelodysplastic Neoplasms: A Systematic Review and Bayesian Meta‐Analysis

Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Roberto Cavalcante Venâncio, Mariana Macambira Noronha, Cilomar Martins, Jonathan L. Berry, Ronald Feitosa Pinheiro

10.1002/hon.70226
View Publication

Low‐Dose Chidamide Maintenance Therapy After Hematopoietic Stem Cell Transplantation for T‐Cell Acute Lymphoblastic Leukemia: A Case Series

Shen‐Hao Liu, Ai‐Ni Deng, Hui‐Ying Li, Qian Wang, Yang Li, Zi‐Fan Zheng, Si‐Man Huang, Han‐Yu Cao, Chao‐Ling Wan, Xiao‐Hui Hu, Hai‐Ping Dai, Sheng‐Li Xue

10.1002/hon.70225
View Publication

Frequently asked questions

How long does it take to publish?

Median submission to first decision is 13 days, median submission to acceptance is 96 days, and median acceptance to publication is 12 days.

Reformat to Hematological Oncology using Livewrite Premium

Is a cover letter required?

A covering letter is required, signed by the corresponding author, stating on behalf of all authors that the work has not been published and is not being considered for publication elsewhere.

Reformat to Hematological Oncology using Livewrite Premium

What are the publication costs?

$4,880 USD / £3,270 GBP / €4,110 EUR APC applies if the open access option is selected and the article is accepted and published.

Reformat to Hematological Oncology using Livewrite Premium

Research Topics

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research CAR-T cell therapy research CNS Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders Acute Myeloid Leukemia Research Acute Lymphoblastic Leukemia research Lung Cancer Treatments and Mutations Chronic Myeloid Leukemia Treatments Multiple Myeloma Research and Treatments T-cell and Retrovirus Studies Monoclonal and Polyclonal Antibodies Research Immune Cell Function and Interaction Cutaneous lymphoproliferative disorders research Cancer Genomics and Diagnostics Immunodeficiency and Autoimmune Disorders Myeloproliferative Neoplasms: Diagnosis and Treatment Hematopoietic Stem Cell Transplantation Cancer Immunotherapy and Biomarkers Protein Degradation and Inhibitors Cancer Treatment and Pharmacology Multiple and Secondary Primary Cancers Diverse Scientific and Economic Studies Human auditory perception and evaluation Educational Robotics and Engineering

Related Journals

NA
Neuropathology and Applied Neurobiology WILEY
JO
Journal of Cancer Research and Clinical Oncology Springer Science+Business Media
Ot
Otolaryngology WILEY
JO
Journal of Diabetes WILEY
JO
Journal of the American Geriatrics Society WILEY
SI
Seminars in Hematology Elsevier BV